fenofibrate has been researched along with Polymyositis in 3 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Polymyositis: Diseases characterized by inflammation involving multiple muscles. This may occur as an acute or chronic condition associated with medication toxicity (DRUG TOXICITY); CONNECTIVE TISSUE DISEASES; infections; malignant NEOPLASMS; and other disorders. The term polymyositis is frequently used to refer to a specific clinical entity characterized by subacute or slowly progressing symmetrical weakness primarily affecting the proximal limb and trunk muscles. The illness may occur at any age, but is most frequent in the fourth to sixth decade of life. Weakness of pharyngeal and laryngeal muscles, interstitial lung disease, and inflammation of the myocardium may also occur. Muscle biopsy reveals widespread destruction of segments of muscle fibers and an inflammatory cellular response. (Adams et al., Principles of Neurology, 6th ed, pp1404-9)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Five patients (median age 68 [54-78], female N =4) with CLD treatment (statin N =4, fenofibrates N =1) have developed iatrogenic polymyositis." | 3.72 | [Polymyositis induced or associated with lipid-lowering drugs: five cases]. ( Bataille, D; Devulder, B; Fauchais, AL; Hachulla, E; Hatron, PY; Iba Ba, J; Kyndt, X; Lambert, M; Maurage, P; Michon Pasturel, U; Parent, D; Queyrel, V; Vanhille, P, 2004) |
| "Statin monotherapy is generally well tolerated, with a low frequency of adverse events." | 2.42 | Safety of statins: focus on clinical pharmacokinetics and drug interactions. ( Bellosta, S; Corsini, A; Paoletti, R, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fauchais, AL | 1 |
| Iba Ba, J | 1 |
| Maurage, P | 1 |
| Kyndt, X | 1 |
| Bataille, D | 1 |
| Hachulla, E | 1 |
| Parent, D | 1 |
| Queyrel, V | 1 |
| Lambert, M | 1 |
| Michon Pasturel, U | 1 |
| Hatron, PY | 1 |
| Vanhille, P | 1 |
| Devulder, B | 1 |
| Bellosta, S | 1 |
| Paoletti, R | 1 |
| Corsini, A | 1 |
| Cherif, O | 1 |
| Karma, F | 1 |
| Ben Amor, G | 1 |
| Kochbati, S | 1 |
| Ben Amor, B | 1 |
| Rokbani, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Liver Injury by Statins in Coronary Heart Disease (CHD) Patients With History of Hepatitis B Virus (HBV) Infection[NCT02808299] | 600 participants (Anticipated) | Observational | 2016-12-31 | Not yet recruiting | |||
| A Multicenter Study Of Nutraceutical Drinks For Cholesterol (Evaluating Effectiveness and Tolerability)[NCT01152073] | 79 participants (Actual) | Interventional | 2009-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for fenofibrate and Polymyositis
| Article | Year |
|---|---|
Safety of statins: focus on clinical pharmacokinetics and drug interactions.
Topics: Binding, Competitive; Biological Availability; Calcium Channel Blockers; Chemical and Drug Induced L | 2004 |
Safety of statins: focus on clinical pharmacokinetics and drug interactions.
Topics: Binding, Competitive; Biological Availability; Calcium Channel Blockers; Chemical and Drug Induced L | 2004 |
Safety of statins: focus on clinical pharmacokinetics and drug interactions.
Topics: Binding, Competitive; Biological Availability; Calcium Channel Blockers; Chemical and Drug Induced L | 2004 |
Safety of statins: focus on clinical pharmacokinetics and drug interactions.
Topics: Binding, Competitive; Biological Availability; Calcium Channel Blockers; Chemical and Drug Induced L | 2004 |
2 other studies available for fenofibrate and Polymyositis
| Article | Year |
|---|---|
[Polymyositis induced or associated with lipid-lowering drugs: five cases].
Topics: Aged; Antibodies, Antinuclear; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhi | 2004 |
[Hypothyroidism and muscular toxicity from fenofibrate, report of a case revealed by polymyositis].
Topics: Female; Fenofibrate; Humans; Hypolipidemic Agents; Hypothyroidism; Middle Aged; Polymyositis | 1997 |